Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Diane D, Wang"'
Autor:
Pooneh Soltantabar, Ali Alhadab, Jennifer Hibma, Satrajit Roychoudhury, Diane D. Wang, Carlo Bello, Mohamed Elmeliegy
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 2001-2012 (2023)
Abstract Exposure‐response (E‐R) analyses are an integral component of understanding the benefit/risk profile of novel oncology therapeutics. These analyses are typically conducted using data from the treatment arm to characterize the relationshi
Externí odkaz:
https://doaj.org/article/fc86ec91e39a4355b28b5b67d3aa6976
Autor:
Norihiko Oharu, Patrick Schnell, Keith D. Wilner, Jack Mardekian, Michelle Yu-Kite, Diane D. Wang, Jillian Motyl Rockland, Dongrui R. Lu, Todd VanArsdale, Jennifer M. Tursi, Albert L. Kraus, Cynthia Huang Bartlett, Matthew J. Cotter, Kenneth R. Carson, Jaclyn Decembrino, Sindy T. Kim, Anala Gossai, Tamara Snow
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:302-309
This report examined the benefits and risks of palbociclib plus endocrine therapy (ET) in men with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Palbociclib was evaluated usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd161687b72b981353a6643c01b43925
https://doi.org/10.1002/cpt.2454
https://doi.org/10.1002/cpt.2454
Autor:
Cen, Guo, Yanke, Yu, Jayeta, Chakrabarti, Sarina A, Piha-Paul, Rebecca, Moroose, Anna, Plotka, Haihong, Shi, Chandrasekar, Durairaj, Diane D, Wang, Zev A, Wainberg
Publikováno v:
British journal of clinical pharmacology, vol 88, iss 7
AimThis phase I study investigated talazoparib pharmacokinetics (PK) and safety in patients with advanced solid tumours and varying degrees of hepatic function.MethodsPatients with advanced solid tumours and normal hepatic function or varying degrees
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26ad904d5c57ef4eb5e7f11f9dcadd2d
https://escholarship.org/uc/item/8k15k9cm
https://escholarship.org/uc/item/8k15k9cm
Autor:
Anna Plotka, Sunil Babu, Sarina Anne Piha-Paul, Chandrasekar Durairaj, Diane D. Wang, Justin Hoffman, H. Hirte, Cristiano Ferrario, Haihong Shi, Jayeta Chakrabarti
Publikováno v:
Clinical Pharmacokinetics
Background Pharmacokinetic (PK) studies suggest that talazoparib is primarily eliminated unchanged via renal excretion. The current study investigated how varying degrees of renal impairment may affect the PK of talazoparib, and evaluated the safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e13a5ec6e86c27df86fa3e619edea50a
http://europepmc.org/articles/PMC8249284
http://europepmc.org/articles/PMC8249284
Autor:
Chandrasekar Durairaj, Véronique Diéras, Jenny Zheng, Richard S. Finn, Diane D. Wang, Yanke Yu
Publikováno v:
Targeted Oncology
Background Palbociclib is indicated for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer (ABC). Objective Exposure-response analyses were conducted to evaluate efficacy in Asian versus non-Asian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4237e5487ceb61f6d4aca5bb07be84f
https://doi.org/10.1007/s11523-020-00771-5
https://doi.org/10.1007/s11523-020-00771-5
Publikováno v:
Journal of Clinical Pharmacology
Guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency recommends using Child‐Pugh classification for pharmacokinetic evaluation in noncancer subjects with hepatic impairment (HI). Therefore, dosing recommendati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::126f7ef1c6a576ebc0643e01e0bbf000
http://europepmc.org/articles/PMC7754409
http://europepmc.org/articles/PMC7754409
Autor:
Jennifer K. Litton, Akos Czibere, Yanke Yu, Jenny Zheng, Mohamed Elmeliegy, Diane D. Wang, Iulia Cristina Tudor
Publikováno v:
The Journal of Clinical Pharmacology. 60:1324-1333
In the phase 3 EMBRACA trial, treatment with the poly(ADP-ribose) polymerase inhibitor, talazoparib, led to significantly improved progression-free survival (PFS) compared with chemotherapy (hazard ratio, 0.54; 95% confidence interval, 0.41-0.71; P.0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::673fef0b2c79733a9de4307ea8246304
https://doi.org/10.1002/jcph.1623
https://doi.org/10.1002/jcph.1623
Publikováno v:
Critical Reviews in Oncology/Hematology. 182:103913
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb93323fb444fc62f50744ba4c10e6ce
https://doi.org/10.1016/j.critrevonc.2023.103913
https://doi.org/10.1016/j.critrevonc.2023.103913
Autor:
Linh Nguyen, Diane D. Wang, Anna Plotka, Zev A. Wainberg, A Milillo Naraine, D Kanamori, Justin Hoffman, Jayeta Chakrabarti, RL Moroose, S Babu
Publikováno v:
Cancer Research. 79:P3-14
Background: Talazoparib (TAL), an oral poly ADP-ribose polymerase inhibitor, is under investigation in multiple oncologic clinical trials and has been submitted to the US FDA for use in patients (pts) with germline BRCA-mutated, HER2-negative advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::702b09d09277a8db2eb35a51a1d338d8
https://doi.org/10.1158/1538-7445.sabcs18-p3-14-07
https://doi.org/10.1158/1538-7445.sabcs18-p3-14-07
Publikováno v:
Clinical Pharmacokinetics
Understanding transporter-mediated drug–drug interactions (DDIs) for investigational agents is important during drug development to assess DDI liability, its clinical relevance, and to determine appropriate DDI management strategies. P-glycoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0978741c8a6119d4bb0ee52adf6e9906
https://pubmed.ncbi.nlm.nih.gov/32052379
https://pubmed.ncbi.nlm.nih.gov/32052379